Continuing Education Activity
Upper respiratory tract infections can be defined as self-limited irritation and swelling of the upper airways with associated cough and no signs of pneumonia, in a patient with no other condition that would account for their symptoms, or with no history of chronic obstructive pulmonary disease, emphysema, or chronic bronchitis. Upper respiratory tract infections involve the nose, sinuses, pharynx, larynx, and large airways. This activity examines when an upper respiratory tract infections should be considered on differential diagnosis and how to properly evaluate it. This activity highlights the role of the interprofessional team in caring for patients with this condition.
Objectives:
Describe the pathophysiology of upper respiratory tract infections.
Review the history and physical of a patient with an upper respiratory tract infection.
Outline the management options for upper respiratory tract infections.
Explain interprofessional team strategies for improving care coordination and outcomes in patients with upper respiratory tract infections.
Introduction
A variety of viruses and bacteria can cause upper respiratory tract infections. These cause a variety of patient diseases including acute bronchitis, the common cold, influenza, and respiratory distress syndromes. Defining most of these patient diseases is difficult because the presentations connected with upper respiratory tract infections (URIs) commonly overlap and their causes are similar. Upper respiratory tract infections can be defined as self-limited irritation and swelling of the upper airways with associated cough with no proof of pneumonia, lacking a separate condition to account for the patient symptoms, or with no history of COPD/emphysema/chronic bronchitis.[1] Upper respiratory tract infections involve the nose, sinuses, pharynx, larynx, and the large airways.
Etiology
Common cold continues to be a large burden on society, economically and socially. The most common virus is rhinovirus. Other viruses include the influenza virus, adenovirus, enterovirus, and respiratory syncytial virus. Bacteria may cause roughly 15% of sudden onset pharyngitis presentations. The most common is S. pyogenes, a Group A streptococcus.
Risk factors for a URTI
Close contact with children: both daycares and schools increase the risk fo URI
Medical disorder: People with asthma and allergic rhinitis are more likely to develop URI
Smoking is a common risk factor for URI
Immunocompromised individuals including those with cystic fibrosis, HIV, use of corticosteroids, transplantation, and post-splenectomy are at high risk for URI
Anatomical anomalies including facial dysmorphic changes or nasal polyposis also increase the risk of URI
Epidemiology
Across the country, URIs are one of the top three diagnoses in the outpatient setting. Estimated annual costs for viral URI, not related to influenza, exceeds $22 billion. [2] Upper respiratory tract infections account for an estimated 10 million outpatient appointments a year. Relief of symptoms is the main reason for outpatient visits amongst adults during the initial couple weeks of sickness, and a majority of these appointments result with physicians needless writing of antibiotic prescriptions. Adults obtain a common cold around two to three times yearly whereas pediatrics can have up to eight cases yearly.[3],[4],[5]Fall months see a peak in incidence of common cold caused by the rhinovirus. Upper respiratory tract infections are accountable for greater than 20 million missed days of school and greater than 20 million days of work lost, thus generatinga large economic burden. [6]
Pathophysiology
A URTI usually involves direct invasion of the upper airway mucosa by the organism. The organism is usually acquired by inhalation of infected droplets. Barriers that prevent the organism from attaching to the mucosa include 1) the hair lining that traps pathogens, 2) the mucus which also traps organisms 3) the angle between the pharynx and nose which prevents particles from falling into the airways and 4) ciliated cells in the lower airways that transport the pathogens back to the pharynx.
The adenoids and tonsils also contain immunological cells that attack the pathogens.
Influenza
The incubation period for influenza is 1 to 4 days, and the time interval between symptom onset is estimated to be 3 to 4 days. Viral shedding can occur 1 day before the onset of symptoms. It is believed thatinfluenza can be transferred among humans by direct contact, indirect contact, droplets, or aerosolization. Short distances (<1 meter) aregenerallyrequired for contact and droplet transmission to occur between the source person and the susceptible individual. Airborne transmission may occur over longer distances (>1 m). Most evidence-based data suggest that direct contact and droplet transfer are the predominant modes of transmission for influenza. [7]
Common Cold
The pathogens are responsible for causing the common cold include rhinovirus, adenovirus, parainfluenza virus, respiratory syncytial virus, enterovirus, and coronavirus. The rhinovirus, a species of the Enterovirus genus of the Picornaviridae family, is the most common cause of the common cold and causes up to 80% of all respiratory infections during peak seasons.[8] Dozens of rhinovirus serotypes and frequent antigenic changes among them make identification, characterization, and eradication complex. After deposition in the anterior nasal mucosa, rhinovirus replication and infection are thought to begin upon mucociliary transport to the posterior nasopharynx and adenoids. As soon as 10 to 12 hours after inoculation, symptoms may begin. The mean duration of symptoms is 7 to 10 days, but symptoms can persist for as long as 3 weeks. Nasal mucosal infection and the host's subsequent inflammatory response cause vasodilation and increased vascular permeability. These events result in nasal obstruction and rhinorrhea whereas cholinergic stimulation prompts mucus production and sneezing.
History and Physical
Acute upper respiratory tract infections include rhinitis, pharyngitis, tonsillitis, and laryngitis. Symptoms of URTIs commonly include:
Cough
Sore throat
Runny nose
Nasal congestion
Headache
Low-grade fever
Facial pressure
Sneezing
Malaise
Myalgias
The onset of symptoms usually begins one to three days after exposure and lasts 7–10 days, and can persist up to 3 weeks.
Evaluation
The presence of classical features for rhinovirus infection, coupled with the absence of signs of bacterial infection or serious respiratory illness, is sufficient to make the diagnosis of the common cold. The common cold is a clinical diagnosis, and diagnostic testing is not necessary. When testing for influenza, obtain specimens as close to symptom onset as possible. Nasal aspirates and swabs are the best specimens to obtain when testing infants and young children. For older children and adults, swabs and aspirates from the nasopharynx are preferred. Rapid strep swabs can be used to rule out bacterial pharyngitis, which could help decrease number of antibiotics being prescribed for these infections.
Treatment / Management
The goal of treatment for the common cold is symptom relief. Decongestants and combination antihistamine/decongestant medications can limit cough, congestion, and other symptoms in adults.[9] Avoid cough preparations in children.[10] H1-receptor antagonists may offer a modest reduction of rhinorrhea and sneezing during the first 2 days of a cold in adults. [3] First-generation antihistamines are sedating, so advise the patient about caution during their use. Topical and oral nasal decongestants (i.e., topical oxymetazoline, oral pseudoephedrine) have moderate benefit in adults and adolescents in reducing nasal airway resistance.[10], [3] Evidence-based data does not support the use of antibiotics in the treatment of the common cold because they do not improve symptoms or shorten the course of illness.[10], [3] There is also a lack of convincing evidence supporting the use of dextromethorphan for acute cough.
According to a Cochrane Review,[11] vitamin C used as daily prophylaxis at doses of =0.2 grams or more had a "modest but consistent effect" on the duration and severity of common cold symptoms (8% and 13% decreases in duration for adults and children, respectively). When taken therapeutically after the onset of symptoms, however, high-dose vitamin C has not shown clear benefit in trials.[11]
Early antiviral treatment for influenza infection shortens the duration of influenza symptoms, decreases the length of hospital stays, and reduces the risk of complications.[Recommendations for the treatment of influenza are updated frequently by the Centers for Disease Control and Prevention based on epidemiologic data and antiviral resistance patterns. Give antiviral therapy for influenza within 48 hours of symptom onset (or earlier), and do not delay treatment for laboratory confirmation if a rapid test is not available. Antiviral treatment can provide benefit even after 48 hours in pregnant and other high-risk patients.[12]
Vaccination is the most effective method of preventing influenza illness. Antiviral chemoprophylaxis is also helpful in preventing influenza (70% to 90% effective) and should be considered as an adjunct to vaccination in certain scenarios or when vaccination is unavailable or not possible. Generally, antiviral chemoprophylaxis is used during periods of influenza activity for (1) high-risk persons who cannot receive vaccination (due to contraindications) or in whom recent vaccination does not, or is not expected to, afford a sufficient immune response; (2) controlling outbreaks among high-risk persons in institutional settings; and (3) high-risk persons with influenza exposures. [13]
Differential Diagnosis
Common Cold
Allergic rhinitis
Sinusitis
Tracheobronchitis
Pneumonia
Influenza
Atypical Pneumonia
Pertussis
Epiglottitis
Streptococcal Pharyngitis/Tonsillitis
Infectious Mononucleosis
Prognosis
URI are common during the winter season and for the most part, are benign, but they can seriously affect the quality of life for a few weeks. A few individuals may develop pneumonia, meningitis, sepsis, and bronchitis. Each year, there are isolated cases of death reported from a URI. Time off work and school is very common. In addition, patients spend billions of dollars on worthless remedies. There is little evidence that any treatment actually shortens the duration of a viral URI. Even the vaccine only works in 40-60% of individuals, at best.
Complications
Complications of upper respiratory tract infections are relatively rare, except with influenza. Complications of influenza infection include primary influenza viral pneumonia; secondary bacterial pneumonia; sinusitis; otitis media; coinfection with bacterial agents; and exacerbation of preexisting medical conditions, particularly asthma and chronic obstructive pulmonary disease. Pneumonia is one of the most common complications of influenza illness in children and contributes significantly to morbidity and mortality.
Enhancing Healthcare Team Outcomes
Upper respiratory tract infections are one of the most common illnesses that healthcare workers will encounter in an outpatient setting. The infection may vary from the common cold to a life-threateningillness like acute epiglottitis. Because of the diverse causes and presentation, upper respiratory tract infections are best managed by an interprofessional team.
The key is to avoid over-prescribing of antibiotics but at the same timenot missing a life-threatening infection. Nurse practitioners who see these patients should freely communicate with an infectious disease expert if there is any doubt about the severity of the infection. The pharmacist should educate the patient on URI and to refrain from overusing unproven products.
Similarly, the emergencydepartment physician should not readily discharge patients home with antibiotics for the common cold. Overall, upper respiratory tract infections lead to very high disability for short periods. Absenteeism from work and schools is common; in addition,the symptoms can be annoying and extreme fatigue is the norm. Patients should be encouraged to drink ample fluids, rest, discontinue smoking and remain compliant with the prescribed medications.[14]
Nursing can monitor the patient's condition and symptoms, counsel on medication compliance, and report any concerns to the clinicians managing the case. INterprofessinoal cooperation is key to good outcomes. [Level 5]
Finally, clinicians should urge patients to get vaccinated before the flu season. While the vaccine may not decrease the duration of the infection, the symptoms are much less severe.
The outcomes in most patients are good, particularly with the interprofessional team approach. [Level 5]
References
- 1.
Wenzel RP, Fowler AA. Clinical practice. Acute bronchitis. N Engl J Med. 2006 Nov 16;355(20):2125-30. [PubMed: 17108344]
- 2.
Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003 Feb 24;163(4):487-94. [PubMed: 12588210]
- 3.
Arroll B. Common cold. BMJ Clin Evid. 2008 Jun 09;2008 [PMC free article: PMC2907967] [PubMed: 19450292]
- 4.
Winther B, Gwaltney JM, Mygind N, Hendley JO. Viral-induced rhinitis. Am J Rhinol. 1998 Jan-Feb;12(1):17-20. [PubMed: 9513654]
- 5.
Simasek M, Blandino DA. Treatment of the common cold. Am Fam Physician. 2007 Feb 15;75(4):515-20. [PubMed: 17323712]
- 6.
Adams PF, Hendershot GE, Marano MA., Centers for Disease Control and Prevention/National Center for Health Statistics. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10. 1999 Oct;(200):1-203. [PubMed: 15782448]
- 7.
Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza A in human beings. Lancet Infect Dis. 2007 Apr;7(4):257-65. [PubMed: 17376383]
- 8.
Heikkinen T, Järvinen A. The common cold. Lancet. 2003 Jan 04;361(9351):51-9. [PMC free article: PMC7112468] [PubMed: 12517470]
- 9.
Irwin RS, Baumann MH, Bolser DC, Boulet LP, Braman SS, Brightling CE, Brown KK, Canning BJ, Chang AB, Dicpinigaitis PV, Eccles R, Glomb WB, Goldstein LB, Graham LM, Hargreave FE, Kvale PA, Lewis SZ, McCool FD, McCrory DC, Prakash UBS, Pratter MR, Rosen MJ, Schulman E, Shannon JJ, Hammond CS, Tarlo SM. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan;129(1 Suppl):1S-23S. [PMC free article: PMC3345522] [PubMed: 16428686]
- 10.
Fashner J, Ericson K, Werner S. Treatment of the common cold in children and adults. Am Fam Physician. 2012 Jul 15;86(2):153-9. [PubMed: 22962927]
- 11.
Douglas RM, Hemilä H, Chalker E, Treacy B. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000980. [PubMed: 17636648]
- 12.
Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, Louie J, Doyle TJ, Crockett M, Lynfield R, Moore Z, Wiedeman C, Anand M, Tabony L, Nielsen CF, Waller K, Page S, Thompson JM, Avery C, Springs CB, Jones T, Williams JL, Newsome K, Finelli L, Jamieson DJ., Pandemic H1N1 Influenza in Pregnancy Working Group. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010 Apr 21;303(15):1517-25. [PMC free article: PMC5823273] [PubMed: 20407061]
- 13.
Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ, Neuzil KM, Pavia AT, Tapper ML, Uyeki TM, Zimmerman RK., Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009 Apr 15;48(8):1003-32. [PMC free article: PMC7107965] [PubMed: 19281331]
- 14.
Le Maréchal M, Tebano G, Monnier AA, Adriaenssens N, Gyssens IC, Huttner B, Milanic R, Schouten J, Stanic Benic M, Versporten A, Vlahovic-Palcevski V, Zanichelli V, Hulscher ME, Pulcini C., DRIVE-AB WP1 group. Quality indicators assessing antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. J Antimicrob Chemother. 2018 Jun 01;73(suppl_6):vi40-vi49. [PMC free article: PMC5989608] [PubMed: 29878218]
Disclosure: Micah Thomas declares no relevant financial relationships with ineligible companies.
Disclosure: Paul Bomar declares no relevant financial relationships with ineligible companies.
